BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37386008)

  • 21. The comparative role of immunohistochemistry and electron microscopy in the identification of myogenic differentiation in soft tissue pleomorphic sarcomas.
    Franchi A; Massi D; Santucci M
    Ultrastruct Pathol; 2005; 29(3-4):295-304. PubMed ID: 16036884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.
    Massi D; Beltrami G; Capanna R; Franchi A
    Eur J Surg Oncol; 2004 Dec; 30(10):1131-6. PubMed ID: 15522563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.
    Casali PG
    Ann Oncol; 2012 Sep; 23 Suppl 10():x167-9. PubMed ID: 22987955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma.
    Piano MA; Brunello A; Cappellesso R; Del Bianco P; Mattiolo A; Fritegotto C; Montini B; Zamuner C; Del Fiore P; Rastrelli M; Sommariva A; De Salvo GL; Montesco MC; Rossi CR; Zagonel V; Calabrò ML
    Clin Cancer Res; 2020 Jun; 26(12):2921-2931. PubMed ID: 32127392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons from genetic profiling in soft tissue sarcomas.
    Nilbert M; Meza-Zepeda LA; Francis P; Berner JM; Namløs HM; Fernebro J; Myklebost O
    Acta Orthop Scand Suppl; 2004 Apr; 75(311):35-50. PubMed ID: 15188664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic research in sarcomas - current status and future opportunities.
    Burns J; Wilding CP; L Jones R; H Huang P
    Semin Cancer Biol; 2020 Apr; 61():56-70. PubMed ID: 31722230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.
    Nassif EF; Blay JY; Massard C; Dufresne A; Brahmi M; Cassier P; Ray-Coquard I; Pautier P; Leary A; Sunyach MP; Bahleda R; Levy A; Le Pechoux C; Honoré C; Mir O; Le Cesne A
    ESMO Open; 2022 Apr; 7(2):100425. PubMed ID: 35255445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
    Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
    BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histology-driven chemotherapy in soft tissue sarcomas.
    Scurr M
    Curr Treat Options Oncol; 2011 Mar; 12(1):32-45. PubMed ID: 21359911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.
    Villacis RA; Silveira SM; Barros-Filho MC; Marchi FA; Domingues MA; Scapulatempo-Neto C; Aguiar S; Lopes A; Cunha IW; Rogatto SR
    PLoS One; 2014; 9(7):e102281. PubMed ID: 25028927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types.
    Murray E; Hernychová L; Scigelova M; Ho J; Nekulova M; O'Neill JR; Nenutil R; Vesely K; Dundas SR; Dhaliwal C; Henderson H; Hayward RL; Salter DM; Vojtěšek B; Hupp TR
    J Proteome Res; 2014 May; 13(5):2543-59. PubMed ID: 24661138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.
    Toulmonde M; Lucchesi C; Verbeke S; Crombe A; Adam J; Geneste D; Chaire V; Laroche-Clary A; Perret R; Bertucci F; Bertolo F; Bianchini L; Dadone-Montaudie B; Hembrough T; Sweet S; Kim YJ; Cecchi F; Le Loarer F; Italiano A
    EBioMedicine; 2020 Dec; 62():103131. PubMed ID: 33254023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions.
    Das S; Idate R; Lana SE; Regan DP; Duval DL
    Sci Rep; 2023 Jun; 13(1):10422. PubMed ID: 37369741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas.
    Binh MB; Guillou L; Hostein I; Château MC; Collin F; Aurias A; Binh BN; Stoeckle E; Coindre JM
    Am J Surg Pathol; 2007 Oct; 31(10):1557-66. PubMed ID: 17895758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Medical treatment of soft tissue sarcomas based on the histological subtype].
    Pápai Z
    Magy Onkol; 2014 Mar; 58(1):53-8. PubMed ID: 24712007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLI1 Immunohistochemistry Distinguishes Mesenchymal Neoplasms With GLI1 Alterations From Morphologic Mimics.
    Parrack PH; Mariño-Enríquez A; Fletcher CDM; Hornick JL; Papke DJ
    Am J Surg Pathol; 2023 Apr; 47(4):453-460. PubMed ID: 36693363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
    Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
    Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.